I shared a post about Ocrevus yesterday and got a lot of responses — so I wanted to follow up with more detailed information that I think the MS community should know. Please let me know if I’ve misunderstood anything. I’m just sharing what I found, in the hope it helps someone else. This comes directly from the FDA’s medical review of the ORATORIO trial — the only study used to approve Ocrevus for Primary Progressive MS (PPMS). ⸻ ⚠️ What the FDA Found (but most people don’t hear about): 📉 Very small benefit — for many, none at all The drug didn’t show meaningful help for several key groups: • Women: less than 1% improvement • People over 45: about 1% • Diagnosed over 5 years: no benefit • Had symptoms over 10 years: no benefit 📊 No benefit for women In fact, more women got worse on Ocrevus than on placebo — meaning no benefit at all for women in the trial. 🔍 FDA says the numbers were boosted The study used a method called “imputation” to guess missing results. These guesses made the results look better. Without them, the main result wasn’t statistically significant — which means the drug’s effects could’ve just been chance. ⏳ Benefit faded after 18 weeks According to the FDA, the effect stopped after about 4 months. After that, people on Ocrevus and on placebo got worse at the same rate. 🚨 High dropout rates • 1 in 3 people on placebo dropped out • 1 in 5 people on Ocrevus dropped out That’s a major red flag — especially when the overall benefit was only 4–7%. It makes the results less reliable. ⚠️ The trial broke some basic rules In some cases, people’s “pre-treatment” condition was measured after they had already received the drug — which violates a core principle in clinical trials. ⸻ 🤔 Why am I sharing this? Because people living with PPMS deserve transparency, not just glossy marketing. If you’re on Ocrevus or considering it, you have the right to know what the FDA actually found when they reviewed the data. 🧾 Full source: FDA Medical Review PDF: 👉 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761053orig1s000medr.pdf (See Table 14 and Table 126) ⸻ This post is for information only — not medical advice. Please speak to your doctor before making any decisions about treatment. #MSHope #Ocrevus #PPMS #InformedConsent #KnowTheFacts #TruthMatters #DoWhatWorksForYou